MRTX1133
reversible KRASG12D inhibitor preclinical efficacy in cancer model from SBDD around KRASG12C inhibitor Journal of Medicinal Chemistry Mirati Therapeutics, San Diego, CA
Molecules of the Month - December 2021
Molecules of the Month
- MRTX1133
- CC-90001
- HTT-D3
- ulotaront
- velsecorat
- “compound 22”
- “compound 43b”
- RP-3500
- HR011303
- “compound 54c”
- “compound 17a”
- “compound 3”
- “compound 24”
- “compound 25”